Literature DB >> 11325449

Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules.

C Delcambre1, J H Jacob, D Pottier, M Gignoux, J M Ollivier, B Vie, A Roussel, P Segol.   

Abstract

BACKGROUND AND
PURPOSE: A retrospective study comparing chemotherapy and radiation, esophagectomy alone versus preoperative radiochemotherapy and surgery in localized squamous-cell esophageal carcinoma.
MATERIALS AND METHODS: Between 1989 and 1995, 139 patients (40 stage I, 77 stage IIA and 22 stage IIB according to the UICC 78 TNM classification) were treated in two different institutions. They were divided into three groups according to the treatment proposed: E group (treatment by esophagectomy; n = 30), RCT+E group (treatment by preoperative radiochemotherapy and esophagectomy; n = 46), RCT group (treatment by radiochemotherapy; n = 63). Factors like age, tumor localization and stage were similar in all groups. An intention to treat analysis was made.
RESULTS: The E group showed no postoperative mortality, while in the RCT+E group, the surgery mortality was 12.8%. The mortality after RCT was 1.7%. After preoperative radiochemotherapy, a pathological complete response was observed in 25% of cases and the curative resection rate was higher (82% after RCT + E versus 60% after E). The 5-year survival difference between the three groups was not relevant (E group, 12.6%; RCT group, 25.8%; RCT + E group, 38.7%). The median survival was 29, 24 and 28.5 months, respectively. The event-free survival was identical for the E group and the RCT group. For patients treated by radiochemotherapy, local and/or distant relapses were significantly reduced by esophagectomy (relapses occurred in 51% of patients in the RCT + E group versus 75% in the RCT group, P = 0.017). Palliative care (dilatations, prosthesis, gastrostomy or jejunostomy) to improve dysphagia was necessary for 38% of patients treated by exclusive radiochemotherapy versus 11% of patients treated by surgery (P = 0.001).
CONCLUSIONS: Treatments by esophagectomy or radiochemotherapy were not significantly different. Preoperative radiochemotherapy and surgery lead to a higher survival rate than exclusive radiochemotherapy, however, with a high postoperative mortality rate. This study suggests the relevance of a prospective randomized trial to compare RCT+E and RCT alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325449     DOI: 10.1016/s0167-8140(01)00307-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome.

Authors:  Arif Deniz Ordu; Carsten Nieder; Hans Geinitz; Philipp Günther Kup; Lisa Felicia Deymann; Vera Scherer; Stephanie E Combs; Khashayar Fakhrian
Journal:  Strahlenther Onkol       Date:  2014-11-18       Impact factor: 3.621

2.  Analysis of different fractionations of three-dimensional conformable radiotherapy for esophageal cancer.

Authors:  Zhiqian Ma; Yan Zhang; Xiaofang Chen; Chaoxing Liu; Huijun Xu; Peng Zhao
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Computed tomography-based radiomics analysis to predict lymphovascular invasion in esophageal squamous cell carcinoma.

Authors:  Hui Peng; Qiuxing Yang; Ting Xue; Qiaoling Chen; Manman Li; Shaofeng Duan; Bo Cai; Feng Feng
Journal:  Br J Radiol       Date:  2021-12-15       Impact factor: 3.039

4.  Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly.

Authors:  Julian A Abrams; Donna L Buono; Joshua Strauss; Russell B McBride; Dawn L Hershman; Alfred I Neugut
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

5.  High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED).

Authors:  Maria C López Carrizosa; P Maria Samper Ots; A Rodríguez Pérez; A Sotoca; J Sáez Garrido; M M de Miguel
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.340

6.  Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A).

Authors:  Lan Wang; Xin Wang; Xuejiao Ren; Chun Han; Zefen Xiao; Shuchai Zhu; Xueying Qiao; Zhiguo Zhou; Wenbin Shen; Junqiang Chen; Qingsong Pang; Wencheng Zhang; Yidian Zhao; Xiaomin Wang; Xinchen Sun; Xiaolin Ge; Kaixian Zhang; Miaomiao Hu; Gaofeng Li; Miaoling Liu; Yadi Wang
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.